 SALT LAKE CITY, Dec. 8, 2020 PRNewswire -- Lipocine Inc. NASDAQ: LPCN, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration FDA has granted tentative approval to TLANDO, its oral... 